急重症患者高钾血症的管理
该综述检索MEDLINE与EMBASE(1938年1月1日至2018年7月1日,遵循PRISMA声明),回顾急重症患者高钾血症治疗策略的作用机制、预期疗效与副作用。高钾血症是潜在危及生命的电解质异常,可致急重症患者心脏电生理紊乱。常用疗法各有 morbid 风险:胰岛素联合葡萄糖(低血糖/血糖异常并发症常见)、β-2受体激动剂(潜在心肌缺血与心律失常)、酸中毒患者高渗碳酸氢钠输注(大量高渗钠负荷)、肾脏替代治疗(有效但有创)。降钾药物可致血钾快速下降,引起心脏过度兴奋和节律紊乱。
要点
- 高钾血症可致急重症患者心脏电生理紊乱,为潜在危及生命的电解质异常。
- 胰岛素联合葡萄糖治疗与频繁的血糖异常并发症相关。
- β-2受体激动剂治疗与潜在心肌缺血和心律失常相关。
- 酸中毒患者输注高渗碳酸氢钠代表大量高渗钠负荷。
- 降钾药物可致血钾快速下降,引起心脏过度兴奋和节律紊乱。
适用人群与场景
- 急重症患者(acutely ill patient)
处置流程与药物剂量
- 胰岛素与葡萄糖同时给药(associated with frequent dysglycemic complications)。
- β-2受体激动剂(associated with potential cardiac ischemia and arrhythmias)。
- 酸中毒患者输注高渗碳酸氢钠(representing a large hypertonic sodium load)。
- 肾脏替代治疗(effective but invasive)。
红旗征与不能漏的情况
- 高钾血症可致心脏电生理紊乱,为潜在危及生命的电解质异常。
- 降钾药物可致血钾快速下降,引起心脏过度兴奋和节律紊乱。
研究设计与关键结果
- 综述检索MEDLINE与EMBASE,纳入1938年1月1日至2018年7月1日发表的英文相关文献,遵循PRISMA声明,优先选择近10年报告及高度相关的较早文献。
- 高钾血症是潜在危及生命的电解质异常,可致急重症患者心脏电生理紊乱。
- 常用高钾血症治疗可能伴随 morbidity:胰岛素联合葡萄糖与频繁血糖异常并发症相关;β-2受体激动剂与潜在心肌缺血和心律失常相关;酸中毒患者高渗碳酸氢钠输注代表大量高渗钠负荷;肾脏替代治疗有效但有创。
- 降钾药物可致血钾快速下降,导致心脏过度兴奋和节律紊乱。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为:高钾血症治疗不应仅关注特定疗法降低血钾水平的能力,还应关注其潜在副作用;根据患者病情与情境个体化治疗可能限制风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: To review the mechanisms of action, expected efficacy and side effects of strategies to control hyperkalemia in acutely ill patients.
METHODS: We searched MEDLINE and EMBASE for relevant papers published in English between Jan 1, 1938, and July 1, 2018, in accordance with the PRISMA Statement using the following terms: "hyperkalemia," "intensive care," "acute kidney injury," "acute kidney failure," "hyperkalemia treatment," "renal replacement therapy," "dialysis," "sodium bicarbonate," "emergency," "acute." Reports from within the past 10 years were selected preferentially, together with highly relevant older publications.
RESULTS: Hyperkalemia is a potentially life-threatening electrolyte abnormality and may cause cardiac electrophysiological disturbances in the acutely ill patient. Frequently used therapies for hyperkalemia may, however, also be associated with morbidity. Therapeutics may include the simultaneous administration of insulin and glucose (associated with frequent dysglycemic complications), β-2 agonists (associated with potential cardiac ischemia and arrhythmias), hypertonic sodium bicarbonate infusion in the acidotic patient (representing a large hypertonic sodium load) and renal replacement therapy (effective but invasive). Potassium-lowering drugs can cause rapid decrease in serum potassium level leading to cardiac hyperexcitability and rhythm disorders.
CONCLUSIONS: Treatment of hyperkalemia should not only focus on the ability of specific therapies to lower serum potassium level but also on their potential side effects. Tailoring treatment to the patient condition and situation may limit the risks.
参考来源
- Dépret F, Peacock WF, Liu KD, et al. Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. 2019. PMID: 30820692. doi:10.1186/s13613-019-0509-8
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。